Bionomics IPO Presentation Deck

BNC210 Phase 2b PTSD ATTUNE Study Underway WEEK1 2 3 4 5 6 7 OUTPATIENT BID DOSING Phase 2B 1:1 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED BNC210 MONOTHERAPY IN PTSD PATIENTS -200 Subjects BNC 210 900 mg oral tablet PLACEBO 8 9 SECONDARY ENDPOINTS Various patient-reported symptoms of PTSD, changes in anxiety and depression symptoms, and global and social functioning: Safety & tolerability endpoints 10 11 12 FOLLOW-UP PRIMARY ENDPOINT Investigator-rated PTSD symptoms on CAPS-5 Total Symptom Severity Scores in change from Baseline to Week 12 compared to placebo Fast Track designation from FDA BID-Twice dolly dosing Bionomics CAPS-S-Clinicion Administered P750 Scole for the Diagnostic and Stonitical Manual of Mental Disorders, Sch Edition (DSM-S) 15 ATTUNE Study 22 PHASE 2B Single potential registrational- supporting trial for monotherapy treatment in PTSD KEY INCLUSION CRITERIA Female and male (18-75 years) Current PTSD diagnosis CAPS-5 ≥ 30 (Screening & Baseline) (& ≤ 25% decrease Screening to Baseline) -25 Sites 欧 Topline data expected 1H'23

View entire presentation